GSK advances on plans to sell Lucozade and Ribena brands, Q1 results disappoint

FTSE 100-listed pharmaceuticals group GlaxoSmithKline (GSK) has announced plans to sell its Lucozade and Ribena brands during its less-than-impressive first quarter results, which showed a two per cent contraction in group sales.

FTSE 100-listed pharmaceuticals group GlaxoSmithKline (GSK) has announced plans to sell its Lucozade and Ribena brands during its less-than-impressive first quarter results, which showed a two per cent contraction in group sales.

Some analysts have suggested that the decision to sell the brands could earn the company in the region of £1.0bn.

Advertisement - Article continues below

GSK said that the results reflected the ongoing contribution from 'key growth drivers', which were offset by anticipated 'demanding' prior year comparisons.

Pre-tax profit for the period declined from £1.86bn to £1.41bn year-on-year.

Excluding the divestments primarily of Vesicare and non-core OTC brands, sales rose 2.0% during the period.

Pharmaceuticals and Vaccines sales fell 2.0%, while Consumer Healthcare rose 1.0%.

The group reported an adjusted net cash inflow from operating activities of £1.4bn, up from £1.1bn in the first quarter of 2012.

The group reported that during the period it had delivered core earnings per share of 26.9p and a dividend of 18p.

Sir Andrew Witty, Chief Executive Officer of GlaxoSmithKline, said: "This quarter marks continued strategic delivery for GSK with sales and earnings in line with our expectations, significant pipeline progress and further growth in our returns to shareholders through a 6.0% increase in the dividend."

He said that the group is implementing a "major new change programme" designed to improve the competitiveness of its European Pharmaceuticals business and also restructure its manufacturing and research and development businesses to simplify its operating model and release resources.

"The initial phases of these programmes are progressing well and remain on track to deliver total annual savings of at least £1.0bn by 2016. In the short term, the benefits of our restructuring programmes are not only helping to offset some of the margin pressure we are seeing due to the changing shape of our business but also are supporting the investment behind our continuing preparations for the launch of the pipeline," he said.

GlaxoSmithKline's share price was up 0.57% to 1,688p at 12:58 on Wednesday.




Investment strategy

Broker safety – your questions answered

Cris Sholto Heaton answers more of your questions about the safety of stockbroker accounts
25 Mar 2020
Investment strategy

How demographics affects stock valuations

New research suggests that stock and bond valuations are driven by the age of the population – at least in the US.
24 Feb 2020
Stocks and shares

Do you own shares in Sirius Minerals? Here’s what you need to do now

Mining giant Anglo American has proposed a cash takeover of Yorkshire-based minnow Sirius Minerals. Unhappy shareholders must decide whether to accept…
20 Feb 2020

Why investors should be “cautiously bullish” for 2020

Analysts have been out in force making rosy predictions for stockmarkets in 2020, but while there is certainly a case for optimism, investors should r…
17 Jan 2020

Most Popular


House price crash: UK property prices are falling – so where next?

With UK property prices falling for the first time in eight years, are we about to see a house price crash? John Stepek looks at what’s behind the sli…
2 Jul 2020

How can markets hit new record highs when the economy is in such a mess?

Despite the world being in the midst of a global pandemic, America's Nasdaq stock index just hit an all-time high. And it's not the only index on a bu…
3 Jul 2020

The end of the bond bull market and the return of inflation

Central bank stimulus, surging post-lockdown demand and the end of the 40-year bond bull market. It all points to inflation, says John Stepek. Here’s …
30 Jun 2020